Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MV 140

Drug Profile

MV 140

Alternative Names: MV140; Uromune

Latest Information Update: 06 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunotek SL
  • Developer Immunotek SL; Queens University
  • Class Anti-infectives; Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Urinary tract infections

Most Recent Events

  • 14 Oct 2021 Efficacy and adverse events data from a phase III trial in Urinary tract infections presented at the 51st Annual Meeting of the International Continence Society (ICS-2021)
  • 01 Sep 2021 Efficacy and adverse events data from a phase III trial in urinary tract infections (rUTI) presented by Immunotek at 116th Annual Meeting of the American Urological Association
  • 01 Dec 2020 Immunotek completes a phase III trial in Urinary tract infections (Prevention, Recurrent, In adults, In the elderly) in Spain and the United Kingdom (Sublingual) (NCT02543827)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top